COLO-B.CO - Coloplast A/S
| Previous close | 878.00 |
| Open | 878.00 |
| Bid | 884.40 x 0 |
| Ask | 884.80 x 0 |
| Day's range | 877.00 - 885.00 |
| 52-week range | 728.80 - 993.00 |
| Volume | |
| Avg. volume | 212,230 |
| Market cap | 187.807B |
| Beta (5Y monthly) | 0.22 |
| PE ratio (TTM) | 38.75 |
| EPS (TTM) | 22.83 |
| Earnings date | 17 Aug 2023 |
| Forward dividend & yield | 20.00 (2.30%) |
| Ex-dividend date | 15 May 2023 |
| 1y target est | 956.24 |
Globe NewswireColoplast A/S - Announcement no. 02/2023 - Interim Financial Report, H1 2022/23
H1 2022/23 Interim financial results, H1 2022/23 1 October 2022 - 31 March 2023 Coloplast delivered Q2 organic growth of 8% and 28% EBIT margin1). Reported revenue in DKK was up by 10%. Organic growth rates by business area: Ostomy Care 6%, Continence Care 6%, Voice and Respiratory Care 9% (2 months), Wound and Skin Care 13% (Wound Care 12%), and Interventional Urology 17%.Solid Q2 for Chronic Care with continued good momentum across regions ex. China, which detracted from growth in Ostomy Care
- Globe Newswire
New clinical study demonstrates significant improvement in pulmonary health and related symptoms when using Provox® Life™
A new multi-center, prospective, two-phase clinical trial1 supported by Atos Medical, a leading company in laryngectomy care, demonstrates a significant improvement in cough and sputum symptoms, leading to improved sleep, with Provox Life. In 2020, Atos Medical launched a new range of heat and moisture exchangers (HMEs) and adhesives, aimed at improving pulmonary health and quality of life for people living with a laryngectomy. A growing body of evidence has shown that the superior humidificatio
Globe NewswireStudy shows significant improvement in bladder emptying with Coloplast's Luja™ compared to competitor catheter
Luja Coloplast's intermittent male catheter Luja Study results show that Coloplast’s new intermittent male catheter with 80+ micro-holes, Luja, achieved complete bladder emptying in one free flow* in 90% of catheterisations, while Hollister’s 2-eyelet catheter, VaPro™, achieved this in 52% of catheterisations. Coloplast has finalised its first pivotal clinical study on Luja, a new intermittent male catheter, designed to reduce the risk of urinary tract infections by minimising residual urine and
- Globe Newswire
Coloplast A/S - Allocation of Share Options
Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities. The below transactions concern allocation of share options. For further details, reference is made to Coloplast’s Remuneration Policy which was adopted in 2021. The policy is available on the group website at this
Globe NewswireColoplast launches male catheter designed to reduce the risk of urinary tract infections
Luja Coloplast's new intermittent catheter Luja™ addresses important risk factors for urinary tract infections, a significant burden for people using intermittent catheters as well as healthcare systems as a whole. Luja Coloplast's new intermittent catheter Luja™ addresses important risk factors for urinary tract infections, a significant burden for people using intermittent catheters as well as healthcare systems as a whole. The new intermittent catheter Luja™ addresses important risk factors f
- Globe Newswire
Coloplast A/S - Announcement no. 01/2023 – Interim Financial Report, Q1 2022/23
Q1 2022/23 Interim financial results, Q1 2022/23 1 October 2022 – 31 December 2022 Coloplast delivered a solid start to the year with 7% organic growth and a 29% EBIT margin before special items Coloplast delivered 7% organic growth in Q1. Reported revenue in DKK was up by 18%. Organic growth rates by business area: Ostomy Care 8%, Continence Care 7%, Wound and Skin Care 1% (Wound Care -4%), and Interventional Urology 11%.Solid start in Chronic Care, with strong momentum in Ostomy Care across re
- Globe Newswire
Coloplast A/S - Announcement no. 14/2022 - Articles of Association
Articles of Association for Coloplast A/S as adopted at the Annual General Meeting of Coloplast A/S held today, 1 December 2022 are enclosed. Our mission Making life easier for people with intimate health care needs Our values Closeness... to better understand Passion... to make a difference Respect and responsibility... to guide us Our vision Setting the global standard for listening and responding For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive V
- Globe Newswire
Coloplast A/S - Announcement no. 13/2022 - Decisions at the Annual General Meeting 2022
Today, 1 December 2022, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The proposal on preparation, etc. of the annual report, company announcements and documents for the internal use by the general meeting in English was approved.The annual report for the financial year 2021/22 was approved.Distribution of year-end dividend of DKK 15.00 per share of nominally DKK 1 was approved. In addition to the interim dividend of DKK 5.00 per share of nominal
- Globe Newswire
Coloplast Launches New Catheter in the U.S.
Coloplast’s SpeediCath® Flex Set catheter developed for people living with bladder and urinary problems is now cleared in the U.S. and will be launched in November 2022. The new SpeediCath Flex Set with a “no touch dry sleeve” and an omni-directional tip is available as a catheter and bag solution, also called a Closed System. All SpeediCath® catheters feature Triple Action Coating Technology which is designed to reduce the risk of urethral damage and Urinary Tract Infections (UTIs)*1 and are an
Globe NewswireColoplast appoints new President of its global Interventional Urology business
Tommy Johns Coloplast's new President & Senior Vice President of Interventional Urology, Tommy Johns. Effective January 2, 2023, Tommy Johns will enter a new role as President & Senior Vice President of Coloplast’s global Interventional Urology (IU) business, replacing Steve Blum, who has decided to retire at the end of 2022. "Tommy has been with the company since 2015 and is the right person to lead our IU business going forward. He currently leads the IU Global Marketing & Innovation function,
- Globe Newswire
Coloplast enters into Power Purchase Agreement with Better Energy
The Power Purchase Agreement (PPA) will contribute directly to the construction of a new large solar park and cover 100% of Coloplast’s electricity consumption in Denmark from 2023 onwards. Coloplast has signed a Power Purchase Agreement with Better Energy, equivalent to 9 GWh of new green electricity per year over a ten-year period. The agreement ensures the construction of a new solar park of more than 50 hectares and marks an important step in Coloplast’s sustainability agenda. The solar park
- Globe Newswire
Coloplast A/S - Announcement no. 12/2022 - Notice of Annual General Meeting
The Annual General Meeting of Coloplast A/S will be held on Thursday, 1 December 2022 at 3:30 pm CET at the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk, Denmark. The notice of the Annual General Meeting is enclosed. For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. +45 4911 1111 Aleksandra DimovskaDirector, Investor RelationsTel. +45 4911 1800 /+45 4911 2458Email: dkadim@colop
- Globe Newswire
Coloplast A/S - Announcement no. 11/2022 - Sustainability Report 2021/22
Coloplast is a purpose-driven company: We make life easier for people living with intimate healthcare needs. In 2021/22, we continued to help more than two million users globally, but many user needs remain unmet across our business areas. We strive to build better standards of care, raise the bar with innovative products and create access for as many users as possible. We are building the consumer healthcare company of the future – enabling self-care for chronic users and supporting healthcare
- Globe Newswire
Coloplast A/S - Announcement no. 10/2022 - Annual Report 2021/22 & Remuneration Report 2021/22
Financial highlights for the year 2021/22 Coloplast delivered 6% organic growth for the full year. Reported revenue in DKK was up by 16% to DKK 22,579 million. Organic growth rates by business area were: Ostomy Care 7%, Continence Care 6%, Interventional Urology 9%, Wound & Skin Care 4% (Wound Care alone 4%). Voice and Respiratory Care contributed 6%-points to the reported growth.EBIT before special items amounted to DKK 6,910 million, a 9% increase from last year. The EBIT margin before special
- Globe Newswire
Coloplast A/S Announcement no. 9/2022 - Full-Year Financial Results 2021/22
1 October 2021 - 30 September 2022 Coloplast delivered Q4 organic growth of 5% and 30% EBIT margin before special items Coloplast delivered 5% organic growth in Q4. Reported revenue in DKK was up by 19%. Organic growth rates by business area were: Ostomy Care 5%, Continence Care 6%, Interventional Urology 12%, and Wound & Skin Care -5% (Wound Care -6%). Voice and Respiratory Care contributed 9%-points to reported growth, with high single-digit underlying growth.Continued solid momentum in Chroni
Globe NewswireColoplast launches Saffron™ Fixation System for Prolapse Repair
The Saffron Anchor Smooth, secure anchor design with the smallest polymeric anchor volume available The Saffron Fixation Tool The Saffron Fixation tool offers consistent, reliable deployment and ease of navigation. Coloplast is introducing the Saffron™ Fixation System designed for ease and reliability during pelvic floor reconstruction for women who suffer from pelvic organ prolapse (POP). “Our goal was to create an easy-to-use fixation tool that enables physicians to consistently attach sutures
- Globe Newswire
Coloplast A/S - Announcement no. 08/2022 - Financial Calendar 2022-23
Please see enclosed pdf. For more information and calendar invitations for upcoming events, please visit: https://investor.coloplast.com/investor-relations/financial-calendar-and-events/ Kind regards,Investor RelationsColoplast A/STel. +45 4911 1800 For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. +45 4911 1111 Aleksandra DimovskaDirector, Investor RelationsTel. +45 4911 1800 / +45 4911 2458Email: dkadim@coloplast.com Kristin
- Globe Newswire
Coloplast A/S - Meet the Management event
31 August 2022 Coloplast is hosting a Meet the Management event in Humlebæk, Denmark, today at 11:30 CEST, where the company will provide a progress update on its Strive25 strategy. The event will start with a plenary session, covering a brief financial update on Q3 2021/22, followed by an update on the Strive25 strategy with a key focus on Innovation and the recent acquisition of Atos Medical. In the afternoon, there will be a series of breakout sessions with Executive Management and other key
- Globe Newswire
Coloplast A/S - Announcement no. 07/2022 - Interim Financial Report, 9M 2021/2022
9M 2021/22 Interim financial results, 9M 2021/22 1 October 2021 - 30 June 2022 Coloplast delivered Q3 organic growth of 8% and an EBIT margin of 30%. Unchanged financial guidance for FY 2021/22, with organic growth at 6-7%, reported growth around 15%, and EBIT margin before special items of around 31% Coloplast delivered 8% organic growth in Q3. Reported revenue in DKK was up by 21%. Organic growth rates by business area in Q3 were: Ostomy Care 10%, Continence Care 5%, Interventional Urology 11%
- Globe Newswire
Coloplast A/S - Reminder: Coloplast's Meet the Management event on 31 August 2022 - register by 5 August 2022
Coloplast will host a Meet the Management event on Wednesday, 31 August 2022. Kindly register before 5 August 2022 for in-person attendance. The event will take place between 11.00 - 18.00 CEST (Central European Summer Time), at Coloplast’s Headquarters in Denmark (Holtedam 3, 3050 Humlebaek, Denmark). Coloplast is delighted to invite institutional investors, equity analysts, and media to attend our Meet the Management event 2022. The event will be held in-person at our headquarters in Humlebaek
- Globe Newswire
Coloplast awarded AscenDrive Agreement for Ostomy Products with Premier, Inc.
Coloplast, a global medical device company and leader in intimate healthcare needs, has been awarded an AscenDrive agreement with Premier, Inc. AscenDrive is a national program designed to standardize the care delivery process and help drive the highest-level commitment and savings for members. Effective July 1, 2022, Coloplast is one of two suppliers awarded the AscenDrive contract for ostomy products. Premier is a leading healthcare improvement company uniting an alliance of approximately 4,40
Yahoo Finance VideoSycamore, Franchise Group submit bids for Kohl's
Yahoo Finance Live anchors discuss Sycamore and Franchise Group becoming the latest to submit bids for Kohl’s.